Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 22, 2008

Resolvyx Receives $25M to Bring Anti-Inflammatory Agents into Clinical Development

  • Resolvyx Pharmaceuticals raised $25 million in a Series B financing. The company will use the money to advance its preclinical resolvin compounds into clinical trials this year.

    Resolvins are a family of naturally occurring, small molecule lipid mediators that decrease inflammation. The firm believes that they can be developed to treat a range of diseases including asthma, cardiovascular disease, and multiple eye diseases. In particular, Paul Rubin, M.D., president and CEO, identified two drug candidates, RvE1 and RX-10045, that will benefit from this funding.

    QVT Financial LP led the financing round and was joined by Radius Ventures and Biogen Idec New Ventures, all first-time backers of Resolvyx. Existing venture investors Atlas Venture, CHL Medical Partners, and Flagship Ventures were also part of the round. Resolvyx’ previously closed a $17 million Series A financing in December 2005.

    “Resolvins clearly provide a novel approach to creating a new class of therapeutics for a range of important and underserved diseases,” according to Keith Manchester, M.D., portfolio manager at QVT Financial. “We believe that resolvin therapeutics have blockbuster potential.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »